Health Canada drug identification number

DIN 02456001 — INVEGA TRINZA 525 MG

INVEGA TRINZA is a suspension (extended-release) of Paliperidone Palmitate marketed by JANSSEN INC. The full Paliperidone Palmitate monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.

DIN
02456001
Brand name
INVEGA TRINZA
Active ingredient
Paliperidone Palmitate
Strength
525 MG
Dosage form
SUSPENSION (EXTENDED-RELEASE)
Route
INTRAMUSCULAR
Manufacturer
JANSSEN INC
Health Canada status
MARKETED
Drug class
Atypical (second-generation) antipsychotic

Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.

Other Paliperidone Palmitate products

DINBrandStrengthFormManufacturerStatus
02354233 INVEGA SUSTENNA 100 MG SUSPENSION (EXTENDED-RELEASE) JANSSEN INC MARKETED
02354241 INVEGA SUSTENNA 150 MG SUSPENSION (EXTENDED-RELEASE) JANSSEN INC MARKETED
02354217 INVEGA SUSTENNA 50 MG SUSPENSION (EXTENDED-RELEASE) JANSSEN INC MARKETED
02354225 INVEGA SUSTENNA 75 MG SUSPENSION (EXTENDED-RELEASE) JANSSEN INC MARKETED
02455943 INVEGA TRINZA 175 MG SUSPENSION (EXTENDED-RELEASE) JANSSEN INC MARKETED
02455986 INVEGA TRINZA 263 MG SUSPENSION (EXTENDED-RELEASE) JANSSEN INC MARKETED
02455994 INVEGA TRINZA 350 MG SUSPENSION (EXTENDED-RELEASE) JANSSEN INC MARKETED

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.